Aura Biosciences, Inc.
$7.16 +$0.11 (+1.56%) 1D Market openKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Jul 2
The stock moved +15.0% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Jul 2 -
Jun 10
From its May 5 high, the share price fell 31%.
Peak close $8.90 on May 5; trough close $6.12 on Jun 10. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -31% -
May 4
The stock moved +19.1% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, May 4
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Aura Biosciences, Inc.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.